Mon, Aug. 22, 11:02 AM
Tue, Aug. 9, 11:00 AM
Tue, Jun. 28, 12:46 PM
Tue, Jun. 28, 11:00 AM
Mon, Jun. 27, 12:51 PM
Mon, Jun. 27, 12:05 PM
- Thinly traded nano cap Fibrocell Science (FCSC +40.8%) jumps on almost a 10x surge in volume. Shares are up nearly 60% since Thursday on no particular news.
- The company develops cell and gene therapies for diseases of the skin, connective tissue and joints. Several weeks ago, shares collapsed on the announcement that lead product candidate azficel-T flunked a mid-stage study in patients with vocal cord scarring.
- Previously: Fibrocell's lead product candidate flunks mid-stage study; shares slump 47% premarket (June 8)
Mon, Jun. 27, 11:00 AM
Wed, Jun. 8, 12:46 PM
Wed, Jun. 8, 11:00 AM
Wed, Jun. 8, 9:09 AM
- Thinly traded nano cap Fibrocell Science (NASDAQ:FCSC) is down 47% premarket, albeit on only 3,800 shares, in response to its announcement that its Phase 2 clinical trial assessing lead product candidate azficel-T for the treatment of vocal cord scarring resulting in chronic/severe dysphonia (difficulty in speaking) failed to beat placebo. As a result, the company will cease development and focus its resources on gene therapy candidate FCX-007, being developed in collaboration with Intrexon (NYSE:XON).
- Azficel-T is a personalized gene therapy based on the patient's own cells called fibroblasts, the most common cell in the skin and connective tissue.
Mon, Apr. 25, 9:15 AM
- Thinly traded micro cap Fibrocell Science (NASDAQ:FCSC) is up 7% premarket on light volume in response to its announcement that the FDA has designated gene therapy FCX-013 an Orphan Drug for the treatment of localized scleroderma, a chronic autoimmune disorder characterized by the painful and debilitating thickening of the skin and connective tissue.
- FCX-013, an autologous fibroblast cell designed to break down excess collagen at the site of disease, utilizes Intrexon's (NYSE:XON) gene regulation technology called RheoSwitch which offers transcriptional control of a range of therapeutic genes.
- Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.
Wed, Apr. 20, 12:45 PM
Oct. 9, 2015, 11:51 AM
- Thinly traded micro cap Fibrocell Sciences (FCSC +16.3%) heads north, albeit on light volume, in apparent response to a poster presentation at the American Society of Human Genetics Annual Meeting in Baltimore, MD. The poster, titled "Pre-Clinical Development of a Genetically-Modified Human Dermal Fibroblast for the Treatment of Recessive Dystrophic Epidermolysis Bullosa" (RDEB) contained data from an in vivo pre-clinical study of FCX-007 in severe combined immunodeficiency mice (SCID).
- The study evaluated FCX-007 for toxicology and biological proof-of-concept in RDEB and normal human skin xenografts implanted in SCID mice. Toxicology results at week two and week six after administration showed no test article-related findings (no effects observed related to FCX-007), no tumors in the skin grafts or other organs, no statistical changes in blood chemistry and no apparent systemic distribution of the vector (genetically-modified fibroblast cells).
- Also, data supporting the proof-of-concept showed FCX-007 cells in a human xenograft model expressed COL7 (type VII collagen) that localized to the basement membrane zone where anchoring fibrils are formed. RDEB sufferers do not produce COL7, the main component of anchoring fibrils that connect skin layers. This causes their skin to blister and peel off in response to any kind of friction.
- FCX-007 is Fibrocell's gene therapy candidate for the treatment of RDEB. Its value proposition is the delivery of high levels of COL7 directly to affected areas. Current standard-of-care treatment, bandaging and antibiotics, just address the symptoms.
Sep. 25, 2015, 1:26 PM
- Thinly traded micro cap Fibrocell Sciences (FCSC -22.2%) is off on a 50% spike in volume, albeit on turnover of less than 500K shares, in response to its announcement that the FDA has requested a new toxicology study to support its IND application for the proposed Phase 1/2 study protocol for its gene therapy candidate FCX-007, under development for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The new study should commence in Q4 and the data should be filed sometime in Q1, causing a delay in the start of the trial of six months or more.
- The toxicology study will assess the effects of an injection of FCX-007 in non-grafted SCID (severe combined immunodeficiency) mice. The toxicology study filed with the IND was based on the injection of FCX-007 in RDEB human skin that was xenografted onto SCID mice, which showed no toxicity.
- RDEB, caused by a deficiency in type VII collagen, is a rare inherited disorder characterized by blistering and missing areas of skin.
Sep. 25, 2015, 12:44 PM
Jul. 22, 2015, 12:45 PM
Fibrocell Science, Inc. operates as a autologous cell therapy company, which focuses on developing treatments for skin and connective tissue diseases with unmet medical needs. The company has a pipeline of therapeutic and aesthetic product development programs based on the first Food and Drug... More
Country: United States